• In the past half year ended June 30, 2026, Alpha Tau Medical Ltd. reported a net loss of US$68.75 million, widening from US$18.81 million a year earlier, with basic loss per share from continuing operations rising to US$0.76 from US$0.25.
• This sharp increase in losses highlights how the company’s cost structure and spending priorities are weighing more heavily on its financial profile.
• We’ll now examine how Alpha Tau Medical’s sharply wider half-year loss helps shape the evolving investment narrative around the company.

Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

What Is Alpha Tau Medical's Investment Narrative?

To own Alpha Tau Medical today, you have to believe that Alpha DaRT’s growing clinical footprint in difficult cancers can ultimately justify a business that is still pre-revenue and deeply loss-making. The latest half-year results, with the net loss widening to US$68.75 million and loss per share tripling, sharpen the focus on how long the company can fund its trials and commercialization plans without further dilution. In the near term, key catalysts still center on U.S. regulatory progress for recurrent cSCC and readouts from GBM and pancreatic studies, alongside the Tolmar prostate partnership. However, the size and pace of recent losses now make funding risk a more immediate consideration, especially after a withdrawn US$75 million offering, and that context is an important lens for interpreting the strong share price run into this news.

However, the recent surge in losses raises a funding risk that investors should not ignore. Insights from our recent valuation report point to the potential overvaluation of Alpha Tau Medical shares in the market.

Exploring Other Perspectives

The Simply Wall St Community offers 1 fair value estimate at US$14.40, showing how tightly one set of private investors views Alpha Tau’s worth. Set this against the sharply wider half-year loss and rising funding risk, and it becomes clear why exploring several alternative viewpoints on the company’s prospects matters.

Explore another fair value estimate on Alpha Tau Medical - why the stock might be worth just $14.40!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Alpha Tau Medical research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision.
• Our free Alpha Tau Medical research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Alpha Tau Medical's overall financial health at a glance.

Contemplating Other Strategies?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Uncover the next big thing with 20 elite penny stocks that balance risk and reward.
• The future of work is here. Discover the 39 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Find 51 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.